Protocolsβ€ΊLongevity Foundation Protocol
BeginnerLongevity12 weeks

Longevity Foundation Protocol

Optimize growth hormone pulsatility, support immune homeostasis, and establish a sustainable anti-aging foundation

Patient profile: Adults 40–65 with early signs of age-related decline: low energy, reduced recovery, mild immune dysregulation

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol β†’
⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

CJC-1295 (no DAC)

Primary

Dose

100 mcg

Frequency

5x/week SC

Timing

30 min before bed

Duration

12 weeks

Ipamorelin

Primary

Dose

100 mcg

Frequency

5x/week SC

Timing

Combined with CJC-1295, before bed

Duration

12 weeks

Thymosin Alpha-1

Supporting

Dose

1.5 mg

Frequency

2x/week SC

Timing

Morning, any day

Duration

12 weeks

Monitoring Parameters

  • βœ“IGF-1 at baseline, week 6, week 12
  • βœ“Fasting glucose and insulin (HOMA-IR)
  • βœ“Complete blood count (CBC) β€” monthly
  • βœ“Cortisol (AM) β€” baseline and week 12
  • βœ“Subjective sleep quality (Pittsburgh Sleep Quality Index)
  • βœ“Body composition (DEXA or impedance) β€” baseline and week 12

Expected Outcomes

1

Weeks 1–3: Improved sleep depth and quality, mild fatigue reduction

2

Weeks 4–6: Noticeable energy improvement, faster workout recovery

3

Weeks 7–10: IGF-1 increase (20–40% expected), body recomposition visible

4

Week 12: Comprehensive assessment β€” consider maintenance cycle (4 weeks on / 2 weeks off)

Contraindications

  • βœ—Active malignancy or personal history of hormone-sensitive cancer
  • βœ—Uncontrolled diabetes (HbA1c > 8.5%)
  • βœ—Active pituitary pathology
  • βœ—Pregnancy or breastfeeding
  • βœ—Severe hepatic or renal impairment

Clinical Notes

CJC-1295/Ipamorelin combination mimics the natural GH pulse without suppressing endogenous production. Thymosin Alpha-1 simultaneously regulates T-cell function and NK cell activity β€” a key synergy for patients over 50 where immune senescence is already measurable. Avoid dosing on days when patient is febrile.

Case Study

Clinical Practice Example

Male, 52, executive with chronic low energy, disrupted sleep (waking 2–3x/night), and declining gym performance. Baseline IGF-1 was 98 ng/mL (age-adjusted low). After 12 weeks on this protocol, IGF-1 reached 178 ng/mL. He reported sleeping through the night from week 4 onward, gained 2.1 kg lean mass, and reduced body fat by 1.8%. Continued on a maintenance cycle.